Summary
Anti-Thymocyte Globulin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Myasthenia Gravis (MG) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Myasthenia Gravis (MG). ClinicalTrials.gov lists 1 registered trial linking Anti-Thymocyte Globulin to Myasthenia Gravis (MG): 1 is active or not yet recruiting. The most advanced is Phase 2 (NCT00716066). It plans or enrolled 53 participants. Registered activity dates to 2008. No published literature item is linked to Anti-Thymocyte Globulin and Myasthenia Gravis (MG) in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Myasthenia Gravis ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous complete stable remission (CSR) in 10-20% of patients over 10 years; generalised MG rarely resolves without treatment; ocular MG may remain limited in 50-60%.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 24.0 (trials 4.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 1 total: 0 recruiting, 1 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | CTLA4 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00716066 | Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases 2008 | active, not recruiting | Phase 2 | 53 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CTLA4. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Anti-Thymocyte Globulin approved for Myasthenia Gravis (MG)?
Anti-Thymocyte Globulin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Myasthenia Gravis (MG) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Myasthenia Gravis (MG). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Anti-Thymocyte Globulin in clinical trials for Myasthenia Gravis (MG)?
ClinicalTrials.gov lists 1 registered trial linking Anti-Thymocyte Globulin to Myasthenia Gravis (MG): 1 is active or not yet recruiting. The most advanced is Phase 2 (NCT00716066). It plans or enrolled 53 participants. Registered activity dates to 2008.
What does the evidence show for Anti-Thymocyte Globulin in Myasthenia Gravis (MG)?
Trials of Anti-Thymocyte Globulin in Myasthenia Gravis (MG) are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CTLA4. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.